Clear science, from bench to bedside
Patients increasingly see blood and pathology results in portals before a clinician has called. For UK laboratories in 2026, that makes release rules, interpretive wording and escalation pathways part of the diagnostic safety case, not an afterthought for communications teams.
Shift change is a clinical transition, not an administrative one. This article sets out why informal bench handover is a diagnostic safety risk in UK laboratories and proposes a one-page ledger that makes outstanding work visible without adding another meeting.
Digital pathology promises resilient reporting and faster second opinions, but scanner colour variation can undermine AI validation and cross-site comparison. This article sets out the colour-assurance questions UK laboratories, vendors and commissioners should answer in 2026.
Preanalytical failure is often treated as a specimen problem, yet many errors are shaped earlier by request forms and electronic ordering screens. This article argues that UK pathology ordering interfaces need device-style scrutiny, with a practical audit and redesign checklist for laboratories, primary care and IT teams.
Unvalidated antibodies rarely announce themselves as procurement failures. They reappear as irreproducible blots, wasted technician hours and grant milestones that cannot be defended. This article sets out a practical validation and lot-tracking framework for UK research teams buying reagents in 2026.
Home-sampling kits are moving into mainstream UK diagnostics, but a validation pack that stops at the laboratory bench leaves the most variable preanalytical step unexamined. This article sets out a practical transport-stability protocol for blood and saliva kits, from Royal Mail transit profiles to acceptance criteria and the documentation commissioners will expect.
Annual antimicrobial susceptibility updates can reclassify organisms, alter cascade reporting and change clinician behaviour long after the validation paperwork has been filed. This deep dive examines how UK laboratories can manage EUCAST and CLSI revisions across the LIS, disc diffusion, automated systems and stewardship teams without creating invisible reporting inconsistencies.
Vendor reference intervals are convenient defaults, not universal truths. As UK laboratories plan analyzer replacements, local verification and targeted de novo studies can prevent a new platform from redefining disease by configuration.
Requests to train AI models on biobank tissue and data expose a gap between broad research consent and machine-learning reuse. This release audit sets out the provenance, commercial-use, re-identification and model-documentation checks UK biobanks should complete before samples leave the freezer.
Vendor throughput claims are measured on a laboratory that does not exist. The informal workarounds and invisible handoffs that hold a real NHS pathology service together are the missing specification — and two weeks of structured observation is cheaper than buying the wrong machine.
Point-of-care testing has moved from the margins of UK diagnostics to something closer to a front door. But a rapid test is not a small laboratory, and scaling community testing depends far less on the device than on the arrangements wrapped around it. A practical checklist for commissioners, pharmacy leads and laboratory teams.
Between the needle and the result screen sits a chain of handoffs that few clinicians ever see. This explainer follows a single blood tube through a UK pathology network and examines where preanalytical error creeps in — and which interventions actually close the gap.
A test with excellent sensitivity can still generate more false positives than true ones once it meets a low-prevalence population. This analysis works through the arithmetic, draws on UK screening and lateral flow experience, and sets out the questions commissioners should ask before adoption.
Multiplex respiratory panels are moving from specialist virology centres into routine NHS workflows. The science is elegant; the operational questions are harder, from validation and turnaround to antimicrobial stewardship.
Promising diagnostics and devices rarely fail on the science alone. They stall in the gaps between prototype, regulation and NHS adoption. Here are seven recurring bottlenecks, with UK-specific warning signs and questions to ask before budgets are committed.